Joseph Toerner

472 total citations
11 papers, 331 citations indexed

About

Joseph Toerner is a scholar working on Epidemiology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Joseph Toerner has authored 11 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 3 papers in Infectious Diseases and 3 papers in Pharmacology. Recurrent topics in Joseph Toerner's work include Antibiotic Use and Resistance (3 papers), Clostridium difficile and Clostridium perfringens research (3 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Joseph Toerner is often cited by papers focused on Antibiotic Use and Resistance (3 papers), Clostridium difficile and Clostridium perfringens research (3 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Joseph Toerner collaborates with scholars based in United States, United Kingdom and Japan. Joseph Toerner's co-authors include Rosemary Soave, Christopher C. Whalen, Timothy Flanigan, John Turner, Diane V. Havlir, Donald P. Kotler, Edward Cox, John Farley, Sumathi Nambiar and Frank A. Anania and has published in prestigious journals such as Annals of Internal Medicine, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Joseph Toerner

11 papers receiving 311 citations

Peers

Joseph Toerner

ID

PARAS

EPIDE

MB

SURGE

Maria Ioannidou Greece

P Hovette France

José Luis Fuentes-Allen Mexico

Juan Echevarría Peru

Claire M. Italiano Australia

F. Ajana France

Teresa Cabezas Spain

Valai Bussaratid Thailand

J. Loutit United States

P J Flegg United Kingdom

Maria Ioannidou Greece

Joseph Toerner

112 ×0.7

ID

71 ×0.5

PARAS

162 ×1.3

EPIDE

20 ×0.7

MB

18 ×0.6

SURGE

Citations per year, relative to Joseph Toerner Joseph Toerner (= 1×) peers Maria Ioannidou

Countries citing papers authored by Joseph Toerner

Since Specialization

Citations

This map shows the geographic impact of Joseph Toerner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Toerner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Toerner more than expected).

Fields of papers citing papers by Joseph Toerner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Toerner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Toerner. The network helps show where Joseph Toerner may publish in the future.

Co-authorship network of co-authors of Joseph Toerner

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Toerner. A scholar is included among the top collaborators of Joseph Toerner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Toerner. Joseph Toerner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Toerner, Joseph, et al.. (2024). Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization. npj Vaccines. 9(1). 210–210. 5 indexed citations

2.

Anania, Frank A., et al.. (2020). Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration. Hepatology. 73(5). 2023–2027. 34 indexed citations

3.

Davis, Jonathan M., Gerri Baer, Susan McCune, et al.. (2019). Standardizing Safety Assessment and Reporting for Neonatal Clinical Trials. The Journal of Pediatrics. 219. 243–249.e1. 14 indexed citations

4.

Holland, Thomas L, Diane Bloom, Jamie Roberts, et al.. (2016). Patient and physician attitudes regarding risk and benefit in streamlined development programmes for antibacterial drugs: a qualitative analysis. BMJ Open. 6(11). e013561–e013561. 4 indexed citations

5.

Toerner, Joseph & Daniel B. Rubin. (2016). Advancing New Antibacterial Drug Development for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia. Clinical Infectious Diseases. 63(suppl 2). S37–S38. 3 indexed citations

6.

Bergman, Kimberly, et al.. (2015). The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens. Clinical Infectious Diseases. 61(suppl 1). S32–S33. 18 indexed citations

7.

Nambiar, Sumathi, et al.. (2014). Antibacterial Drug Development: Challenges, Recent Developments, and Future Considerations. Clinical Pharmacology & Therapeutics. 96(2). 147–149. 43 indexed citations

8.

Barber, R., et al.. (1998). Estimation of the effect of neutropenia on rates of clinical bacteraemia in HIV-infected patients. Epidemiology and Infection. 120(1). 71–80. 7 indexed citations

9.

Mathews, W. Christopher, et al.. (1998). Neutropenia Is a Risk Factor for Gram-negative Bacillus Bacteremia in Human Immunodeficiency Virus-infected Patients: Results of a Nested Case-Control Study. American Journal of Epidemiology. 148(12). 1175–1183. 24 indexed citations

10.

Toerner, Joseph & W. Christopher Mathews. (1997). GUIDELINES FOR IMMUNIZATIONS IN HIV-INFECTED PATIENTS. Immunology and Allergy Clinics of North America. 17(2). 195–205. 1 indexed citations

11.

Flanigan, Timothy, Christopher C. Whalen, John Turner, et al.. (1992). Cryptosporidium Infection and CD4 Counts. Annals of Internal Medicine. 116(10). 840–842. 178 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact